Company news

Puma Biotechnology Inc news in 2021

Puma Biotechnology Inc's news releases, calls and decks from 2021, newest first.

View company

Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)

November 22, 2021

Puma Biotechnology Reports Third Quarter 2021 Financial Results

November 3, 2021

Puma Biotechnology Reports Second Quarter 2021 Financial Results

August 4, 2021

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital

July 25, 2021

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer

June 30, 2021

Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting

June 3, 2021

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting

May 18, 2021

Puma Biotechnology Reports First Quarter 2021 Financial Results

May 5, 2021

Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China

February 24, 2021

Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020

January 28, 2021

Calls in 2021

Decks in 2021